Patient-Reported Outcomes Are Changing the Landscape in Oncology Care: Challenges and Opportunities for Payers
A patient-reported outcome (PRO) is a subjective report that comes directly from a patient in regard to his or her health condition or treatment without interpretation by a clinician or anyone else.1 PROs have long provided a unique insight into the effectiveness of novel medical treatments.2 Indeed, PRO questionnaires have been developed to quantify a patient’s self-reported health status in a variety of areas, including symptoms, functioning, quality of life (QOL), and health-related QOL.
Assessing the Value of Patient-Reported Outcomes
Jacqueline Pesa, PhD, MPH, Roxanne Meyer, PharmD, Tiffany P. Quock, MS, PhD, Stacy K. Rattana, RN, BSN, Samir H. Mody, PharmD, MBA
Diabetic peripheral neuropathy (DPN) is one of the most common complications associated with diabetes, occurring in 30% to 50% of patients with type 2 diabetes and affecting approximately 1 million Americans annually.1,2 DPN manifests as spontaneous painful, burning, electric, or shooting sensations in the extremities, with 10% to 20% of patients with DPN experiencing moderate-to-severe pain.3-6 Of these patients, 11% to 26% develop chronic pain, which is defined as pain that continues for an extended period of time that may be associated with a recognizable disease process.
Monitoring for Aberrant Opioid Utilization Patterns a Growing Need in Managed Care
Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes pain, stiffness, swelling, and loss of function in the joints; it occurs when the patient’s immune system attacks healthy tissue. RA is ranked among the highest of all chronic diseases for its adverse impact on health-related quality of life (QOL), limitations in physical function, increased pain and fatigue, and diminished work performance and attendance.1
Assessing the Value of TNF-Alpha Blockers for Patients with Rheumatoid Arthritis
National Burden of Preventable Adverse Drug Events Associated with Inpatient Injectable Medications: Healthcare and Medical Professional Liability Costs
Betsy J Lahue, MPH, Bruce S. Pyenson, FSA, MAAA, Kosuke Iwasaki, FIAJ, MAAA, Helen Blumen, MD, MBA, Susan Forray, FCAS, MAAA, Jeffrey M. Rothschild, MD, MPH
Preventable medication errors have emerged as a prominent cost and quality issue in the United States, and are estimated to impact more than 7 million patients, contribute to 7000 deaths, and cost almost $21 billion in direct medical costs across all care settings annually.1,2 Adverse drug events (ADEs) are harms that result from medication use; when these harms result from a medication error, they are known as “preventable ADEs.”3 The inpatient hospital setting is particularly resource-intensive in terms of care delivered and exposure to potential harms a
Assessment of Treatment Patterns and Patient Outcomes in Levodopa-Induced Dyskinesias (ASTROID): A US Chart Review Study
Barbara Lennert, RN, BSN, MAOM, Wendy Bibeau, PhD, Eileen Farrelly, MPH, Patricia Sacco, MPH, RPh, Tessa Schoor, MD
Parkinson’s disease is a degenerative disorder that is characterized by muscle rigidity, tremors, and motor impairment that often results in progressive disability and severe complications that seriously affect a patient’s health-related quality of life (QOL) and physical functioning.
Parkinson’s Disease: A Complicated but Underappreciated and Undertreated Condition
Aarti A. Patel, PharmD, MBA, Barbara Lennert, RN, BSN, MAOM, Brian Macomson, PharmD, Winnie W. Nelson, PharmD, Gary M. Owens, MD, Samir H. Mody, PharmD, MBA, Jeff Schein, DrPH, MPH
Atrial fibrillation (AF) is the most common clinically significant cardiac arrhythmia, diagnosed in approximately 1% of the general population.1 It is estimated that AF currently affects more than 2 million people in the United States and more than 4 million across the European Union, with the number of US patients with AF estimated to increase 2.5-fold by the year 2050.1,2
The Enormous Impact of Atrial Fibrillation and Stroke on Patients, Payers, and Society
Conceptual and Analytical Considerations toward the Use of Patient-Reported Outcomes in Personalized Medicine
Personalized medicine aims to assist healthcare providers to individualize a patient treatment based on the patient’s attributes, which may include biomarkers, genetics, demographic characteristics, and other covariates. Much progress has been made in recent years in the translational research areas of genomics, proteomics, and metabolomics, and several biomarkers have been identified for a number of important diseases, including atherosclerosis, cancer, and rheumatoid arthritis.
No Physician Treats an Average Patient: Bridging the Gap between Group-Based Data and Patient-Specific Treatment Outcomes
Nausea and vomiting are 2 serious and related side effects of cancer chemotherapy. These adverse effects can cause significant negative impacts on patients’ quality of life and on their ability to comply with therapy. Also, nausea and vomiting can result in anorexia, decreased performance status, metabolic imbalance, wound dehiscence, esophageal tears, and nutritional deficiency.1,2 Despite advances in the prevention and management of chemotherapy-induced nausea and vomiting (CINV), these side effects remain among the most distressing for patients.
Selecting Best Therapies for Control of Chemotherapy-Induced Nausea and Vomiting
Lindsay Sanders, DO, MPH, Anu P. Michael, MD, Scott R. Anderson, MS IV, Loida D. Nguyen, PharmD, BCPS, Zackary A. Johnson, MS II, Quang T. Nguyen, DO, FACP, FACE, FTOS
Scott R. Anderson, MS IV, Lindsay Sanders, DO, MPH, Loida D. Nguyen, PharmD, BCPS, Quang T. Nguyen, DO, FACP, FACE, FTOS
Hypertension, defined as systolic blood pressure (BP) ≥140 mm Hg, diastolic BP ≥90 mm Hg, increases with age, affecting more than 50% of patients aged ≥60 years, and approximately 66% of those aged ≥65 years.1-3 It is well known that by 2030, 1 of 5 Americans is expected to be 65 years or older.
Improving Hypertension Management in the Elderly a Core Clinical Goal
Page 8 of 12
Results 71 - 80 of 120
Results 71 - 80 of 120